GlaukosvsJohnson & Johnson

GKOS and JNJ stock compared: price, dividend, valuation and results, from SEC filings.

GKOS

Glaukos Corporation

$233.08

Value $13.5B

-4.18%
GKOS's page

Glaukos (GKOS) has a market value of $13.5B and Johnson & Johnson (JNJ) $657B. Over the last year, with dividends, GKOS moved +163.7% and JNJ +39.7%. Dividend yield: GKOS none, JNJ 1.94%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    GKOS$13.5B

    JNJ$657B

    JNJ is 49 times GKOS

  • Revenue, 12 months

    GKOS$690M

    JNJ$99.3B

    JNJ is 144 times GKOS

  • Net income, 12 months

    GKOS-$170M

    JNJ$16.1B

  • Operating margin

    GKOS-25.5%

    JNJ–

  • ROIC

    GKOS-19.9%

    JNJ12.4%

    32.3 points apart

  • P/E

    GKOS–

    JNJ40.8

  • Dividend yield

    GKOS0.0%

    JNJ1.9%

    1.9 points apart

  • 5-year return

    GKOS+369.3%

    JNJ+92.0%

    277.3 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

GKOS+369.3%

JNJ+92.0%

20040020222023202420252026
Returns by period
PeriodGKOSWith dividendsJNJWith dividends
1 year since November 17, 2025+163.7%Price +163.7%+39.7%Price +36.6%
3 years since November 17, 2023+263.8%+53.8% a yearPrice +263.8%+98.2%+25.6% a yearPrice +82.1%
5 years since November 17, 2021+369.3%+36.2% a yearPrice +369.3%+92.0%+13.9% a yearPrice +67.0%
10 years since November 18, 2016+602.3%+21.5% a yearPrice +602.3%+208.0%+11.9% a yearPrice +136.4%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

GKOSGlaukosJNJJohnson & Johnson

Valuation

GKOSJNJ
Valuation
Price$233.08$272.70
Market value$13.5B$657B
Enterprise value (EV)$13.4B$685B
P/E–40.8
P/E, 5-year median–21.9
P/B18.98.1
EV/EBIT–38.6
Free cash flow yield0.3%3.1%

Results and growth

GKOSJNJ
Results and growth
Revenue, 12 months$690M$99.3B
Net income, 12 months-$170M$16.1B
Free cash flow, 12 months$36M$20.6B
Earnings per share, 12 months-$2.95$6.59
Revenue growth, year on year32.3%6.1%
Revenue growth a year, past+17.7%over 5 years+2.7%over 5 years
EPS growth a year, past–+14.9%over 5 years

Margins and returns on capital

GKOSJNJ
Margins and returns on capital
Gross margin64.8%67.6%
Operating margin-25.5%–
Net margin-24.6%16.2%
ROIC-19.9%12.4%
ROE-24.3%19.7%

Balance sheet

GKOSJNJ
Balance sheet
Cash$162M$17.2B
Total debt$105M$44.7B
Net debt / EBITDA–1.1
Interest cover-36.6×18.0×

Dividends and buybacks

GKOSJNJ
Dividends and buybacks
Dividend yield–1.9%
Dividend per share, 12 months–$5.28
Dividend growth a year, past–+5.3%over 5 years
Buyback yield–0.9%
Shareholder yield–2.9%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: GKOS or JNJ

Didn't find what you were looking for?

Ask us
Which is bigger, Glaukos or Johnson & Johnson?

By market value, Johnson & Johnson ($657B) is about 48.5 times Glaukos ($13.5B), at today's prices.

How did GKOS and JNJ stock do over the last 10 years?

Since November 18, 2016, GKOS's price moved +602.3% and JNJ's +136.4%. With dividends: GKOS +602.3% (+21.5% a year), JNJ +208.0% (+11.9% a year). Past returns do not predict future ones.

Which pays the higher dividend, GKOS or JNJ?

The dividend yield at today's price is none for Glaukos and 1.94% for Johnson & Johnson. Over the last twelve months they paid – and $5.28 per share.

Which has the higher profit margins, Glaukos or Johnson & Johnson?

Over the last twelve months, the net margin was -24.6% for Glaukos and 16.2% for Johnson & Johnson, and the operating margin -25.5% and –. Revenue was $690M and $99.3B.

Which is the better investment, Glaukos or Johnson & Johnson?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.